2010
DOI: 10.4049/jimmunol.0902810
|View full text |Cite
|
Sign up to set email alerts
|

Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1

Abstract: It has been reported that complement is activated on the surface of activated platelets, despite the presence of multiple regulators of complement activation. To reinvestigate the mechanisms by which activated platelets bind to complement components, the presence of complement proteins on the surfaces of nonactivated and thrombin receptor-activating peptide-activated platelets was analyzed by flow cytometry and Western blot analyses. C1q, C4, C3, and C9 were found to bind to thrombin receptor-activating peptid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
94
0

Year Published

2010
2010
2019
2019

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 94 publications
(98 citation statements)
references
References 40 publications
(42 reference statements)
4
94
0
Order By: Relevance
“…We have detected a decreased C5b9 staining of platelets in compstatintreated groups compared with nontreated controls supporting the involvement of complement in platelet deposition in tissues and subsequent thrombocytopenia. It is known that C3a induces platelet activation and aggregation 27 and that C3 could bind to the platelet surface without 36 or with C5b9 formation. 26 Inhibition of complement activation by a potent inhibitor of C3 activation, a key event common to all 3 complement activation pathways, had organ-protective effects in both early and late The tissues were collected after euthanasia at T ϩ 24 hours.…”
Section: Discussionmentioning
confidence: 99%
“…We have detected a decreased C5b9 staining of platelets in compstatintreated groups compared with nontreated controls supporting the involvement of complement in platelet deposition in tissues and subsequent thrombocytopenia. It is known that C3a induces platelet activation and aggregation 27 and that C3 could bind to the platelet surface without 36 or with C5b9 formation. 26 Inhibition of complement activation by a potent inhibitor of C3 activation, a key event common to all 3 complement activation pathways, had organ-protective effects in both early and late The tissues were collected after euthanasia at T ϩ 24 hours.…”
Section: Discussionmentioning
confidence: 99%
“…Most commonly used anticoagulants are heparin for whole blood studies and sodium citrate for studies that focus on platelet-biomaterial interactions in vitro [52,55]. More recently, hirudin appears in an increasing number of hemocompatibility studies and clinically applied routine test systems [56,57]. The decision for a specific anticoagulant should be driven by the clinical background, the choice of tested blood (e.g.…”
Section: Hemocompatibility Testingmentioning
confidence: 99%
“…These assays focus on the platelet-biomaterial interactions and are well suited to assess the thrombogenic potential of a material, even though, sodium citrate is not applied as a systemic anticoagulant. For in vitro studies focusing on complement activation, anticoagulation with hirudin (commercially available as lepirudin or bivalirudine [68]) appears to mimic physiological conditions more appropriately than other anticoagulants [56,57,69].…”
Section: Hemocompatibility Testingmentioning
confidence: 99%
“…4,27 Furthermore, complements are implicated in participation in antibody mediated destruction of thrombocytes in periphery of patients with active lupus. [28][29][30][31] Based on these studies, we hypothesize that whole blood cells' synthesis of C3 mediate local injury on platelets in SLE patients with TCP. However, we just observed the correlation but have not explored the causal relationship between the pathway and lupus TCP in current study.…”
Section: Discussionmentioning
confidence: 99%